OR 72: Amino acid conjugated small molecule BLX-1002 lowers blood glucose in insulin resistant db/db and ob/ob mice and inhibits TNF-α , IL-6 cytokines

BLX-1002 is a water-soluble, orally active, modified single amino acid derivative with no structural resemblance with any existing compounds. When given orally in obese diabetic db/db orob/ob mice, at a dose of 50 mg/kg body weight per day, it was able to reduce blood glucose by 30-40% compare to vehicle treated animals. Unlike other drugs, it reduced body weight gains in these animal models without any effect in food intake. BLX-1002 significantly lowered blood glycosylated hemoglobin ( 0.8%), free fatty acid (43%), triglyceride (20%) and total cholesterol (28%) levels compare to control group. In high fat diet model, BLX-1002 reduced body weight gain and significantly (p